OAKLAND, Calif.--(BUSINESS WIRE)--ZephyrBiotech LLC was launched today, offering a unique approach for early stage companies, by introducing a combination of interim executives and project management to complete specific tasks to develop biotechnology products. The company has been formed by two highly experienced healthcare executives with extensive track records in the international biopharmaceutical industry. Based in the San Francisco Bay Area, a major center of biopharmaceutical investment, ZephyrBiotech provides interim management professionals and integrated project teams to virtual, seed and early stage (series A to C) biotechnology companies to deliver programs to a point of long term sustainability.
Elise Brownell, Ph.D. (Founding Partner), stated that ZephyrBiotech will work with the client to define the parameters of the project and will then apply an integrated, highly collaborative approach such that a program can be delivered on time with agreed deliverables at a cost effective price. The key to achieving these results rests on combining a high level project management perspective with a collaborative, hands-on approach within the client’s company.
Martin Preuveneers, Ph.D. (Founding Partner), added that ZephyrBiotech is able, through its consultants and advisors, to bring a wide array of competencies and experience to early stage biotechnology companies. These include providing commercial focus to early stage programs, identification of business development targets, preclinical and clinical design and regulatory strategy and preparative work for submission to the regulatory authorities such as the FDA and EMEA.
ZephyrBiotech’s interim project-based strategy offers clear advantages to early stage or incubator ventures, including the opportunity to minimize investment in costly infrastructure, and enabling companies to “hit the ground running” while preserving cash. In addition, ZephyrBiotech will provide a multi functional team of seasoned and experienced consultants in a project based process designed to suit the client.
http://www.zephyrbiotech.com
Contact: ZephyrBiotech Elise Brownell PhD, 510-622-7740 elise.brownell@zephyrbiotech.com Martin Preuveneers PhD, 510-622-7740 martin.preuveneers@zephyrbiotech.com
Source: ZephyrBiotech
